Analyst Update: Infoblox, Marvell Tech, Eli Lilly and Co

Analysts are weighing in today on tech concern Infoblox Inc (NYSE:BLOX), semiconductor producer Marvell Technology Group Ltd. (NASDAQ:MRVL), and drug maker Eli Lilly and Co (NYSE:LLY). Here's a quick roundup of today's brokerage notes on BLOX, MRVL, and LLY.

• BLOX is up 21.9% at $18.33 today, after last night reporting better-than-expected quarterly earnings, and authorizing a $100 million share repurchase program. This morning, DA Davidson raised its price target on Infoblox Inc to $20 -- a 9.1% premium to the shares' current price, but still short of the stock's 12-month consensus price target of $25.58. BLOX has been recovering quickly after hitting a one-year low of $13.22 a week ago, but still sits on a 9.3% loss for 2015. And it appears options traders are expecting more losses -- at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), BLOX has a 50-day put/call volume ratio of 1.24, which ranks higher than 80% of readings taken in the past year.

• MRVL is getting a much-needed boost, last seen trading 4.9% higher at $9.29, after Cowen and Company raised its price target to $12 from $11.50. Since hitting an annual high of $16.78 in February, Marvell Technology Group Ltd. has been sinking hard, hitting a more than two-year low in late October when the company's external accounting firm resigned, and managing only slight gains since then. Many short sellers have already taken their profits on the struggling stock, as short interest currently accounts for only 1.8% of MRVL's float. However, this figure is up 10.3% from the prior reporting period, suggesting bears are starting to target the tech stock once again.

• Another stock getting some love today is LLY, gaining 4.1% to trade at $85.43, after Barclays bumped its rating on the stock up to "overweight" from "equal weight" and increased its price target to $95 from $75. This comes one week after the company's lung cancer treatment was approved by the U.S. Food and Drug Administration (FDA), and is just the latest in a string of analyst upgrades. Eli Lilly and Co has been trending higher for several years, and has added nearly 24% in this year alone. There's still room for more bulls to jump on the stock's bandwagon, though. At present, five of the 12 brokerages following LLY still give it a tepid "hold" rating. And at the ISE, CBOE, and PHLX, the stock's 50-day put/call volume ratio of 0.98 is just six percentage points shy of an annual bearish high. The unwinding of some lingering skepticism could soon send LLY up toward all-time-high territory.